Parthenolide reduces tonic ADORA2A signaling by lowering inflammatory extracellular adenosine tone

Hypothesis 1: Parthenolide does not directly agonize or antagonize ADORA2A; instead it lowers inflammatory adenosine tone in corticostriatal circuits by suppressing NF-kB-driven ectonucleotidase and cytokine programs in astrocytes and microglia. Less extracellular adenosine would reduce tonic ADORA2A signaling and favor D2-linked antidepressant network states. Test: adenosine microdialysis, CD39/CD73 expression, and ADORA2A-cAMP readouts after parthenolide.

Hypothesis 2: Parthenolide covalently perturbs upstream adenosine transport or metabolism, for example ENT1/ENT2 trafficking or adenosine

Hypothesis 1 has the best systems logic, but it is one step removed from the phrase "specifically modulate ADORA2A signaling." Reduced inflammation can improve mood behavior without ADORA2A being the decisive node, so the claim needs pharmacologic rescue with selective ADORA2A agonists/antagonists.

Hypothesis 2 is attractive because it could generate specificity upstream of the receptor, but there is a major promiscuity risk. Parthenolide is an electrophilic sesquiterpene lactone and may alkylate many proteins; any apparent effect on transport or metabolism must survive chemoproteomic selecti

The translation path should start with target-validation rather than medicinal chemistry. Use behavioral and molecular assays in stress paradigms with ADORA2A antagonists, agonists, and genetic loss-of-function to determine whether parthenolide's antidepressant signal collapses when A2A signaling is fixed experimentally.

If the signal truly routes through ADORA2A, the indirect extracellular-adenosine model is the most developable because it suggests measurable biomarkers: adenosine tone, phospho-CREB, DARPP-32 state, and astrocyte/microglial inflammatory markers. Direct receptor chemistry is

{"ranked_hypotheses": [{"title": "Parthenolide reduces tonic ADORA2A signaling by lowering inflammatory extracellular adenosine tone", "description": "NF-kB suppression in glia decreases ectonucleotidase and cytokine programs that sustain extracellular adenosine, indirectly reducing ADORA2A pathway output in mood circuits.", "target_gene": "ADORA2A", "dimension_scores": {"evidence_strength": 0.58, "novelty": 0.64, "feasibility": 0.74, "therapeutic_potential": 0.66, "mechanistic_plausibility": 0.74, "druggability": 0.54, "safety_profile": 0.57, "competitive_landscape": 0.63, "data_availability"